Lilly Aims For Earlier Treatment With Novel Diabetes Drugs
GLP-1/GIP Agonist Tirzepatide Leads Next-Gen Pipeline
Executive Summary
Lilly outlined its tirzepatide-led pipeline of incretin agonists and highlighted its once-weekly basal insulin during a post-ADA event. The company hopes to grow the GLP-1 market overall rather than shift patients from Trulicity.
You may also be interested in...
Lilly Adds To Diabetes Pipeline With Protomer Buyout
After investing in the California biotech, Lilly buys the company in search of safer insulin products. The pharma sees these candidates as pairing with tirzepatide to improve diabetes therapy overall.
Lilly/BI's Jardiance Scores A Win In Heart Failure Where Rivals Have Not
A Phase III trial in heart failure with preserved ejection fraction showed a benefit, which could result in a broad heart failure label for the SGLT2 inhibitor.
Novo Nordisk Hopes To Gradually Build US Access To Obesity Therapy
With US FDA approval of Wegovy for obesity, Novo Nordisk prices the weekly injectable at par with its other obesity brand Saxenda. Ramping up sales will require patient, clinician and payer education, the company says.